Tirzepatide
A dual GIP/GLP-1 receptor agonist FDA-approved for diabetes and weight management, producing the largest weight loss seen in clinical trials.
Always consult a qualified clinician
This information is for educational purposes. Peptide therapy should be guided by a licensed healthcare provider. Connect with a Noho clinician
What is Tirzepatide?
Tirzepatide is the first dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. FDA-approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. It has produced the largest weight loss of any approved medication, with average reductions of 20-26% body weight in clinical trials.
Why People Talk About It
Record-setting weight loss (20-26% body weight)
StrongSuperior blood sugar control vs semaglutide
StrongCardiovascular risk reduction
StrongPotential benefits for sleep apnea and NASH
EmergingHow It Works
Tirzepatide activates two appetite-control hormones at once (GIP and GLP-1), producing a stronger 'full' signal than drugs targeting just one. It also improves how your body handles blood sugar and may help your fat cells work more efficiently.
Common Questions
Safety Information
Common Side Effects
Cautions
- • Same thyroid C-cell tumor warning as GLP-1 agonists
- • Pancreatitis risk
- • Gallbladder events
- • Dose-dependent GI side effects
What We Don't Know
Long-term cardiovascular outcomes data is still being collected. Effects on body composition (muscle vs fat loss) need more study.
Published Research
31 studiesDiscontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis
Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis
Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies
Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis
A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults
Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients
Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis
Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials
Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus
Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis
Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis
Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis
Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trials
Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians
Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial
Evidence that tirzepatide protects against diabetes-related cardiac damages
Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials
Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis
Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials
Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis
Weight loss efficiency and safety of tirzepatide: A Systematic review
Tirzepatide for Obesity Treatment and Diabetes Prevention
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight
Tirzepatide Once Weekly for the Treatment of Obesity
Always consult a qualified clinician
This information is for educational purposes. Peptide therapy should be guided by a licensed healthcare provider. Connect with a Noho clinician
Research Insights
Related Peptides
Semaglutide
StrongBeginnerA GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management, one of the most widely prescribed peptide drugs.
Retatrutide
EmergingAn investigational triple agonist (GIP/GLP-1/glucagon) that produced 24% weight loss in Phase II trials, potentially the most effective obesity drug.
Liraglutide
StrongBeginnerA GLP-1 receptor agonist FDA-approved for diabetes (Victoza) and weight management (Saxenda), the predecessor to semaglutide.
Quick Facts
- Class
- Dual GIP/GLP-1 Receptor Agonist
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Mar 2026
- Citations
- 31PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.
Interested in this peptide? A Noho clinician can help determine if it's right for you.
Talk to a Clinician